Release no 29/2010

Interim report for the six months ended 30th June, 2010
Summary: Affitech A/S successfully raised DKK 153.5 million in new equity
finance in a direct offering during April 2010. Through this equity issue
Affitech has now secured its financial position into early 2012 to continue its
strategy to become a leading human therapeutic antibody company. Affitech A/S
generated a loss of DKK 30.6 million for the first six months of 2010. Revenues
were DKK 1.6 million the first six months of 2010. The net loss includes a net
profit in the first quarter from sales of royalty and milestone rights of DKK
5.9 million deducted by DKK 4.0 million of goodwill that was connected to parts
of these rights. The Company expects a loss of DKK 80-86 million for the total
year.

The full report is attached as a PDF.

For more information please contact:

Affitech A/S:
Martin Welschof, Managing Director
Tel # +47 9512 8137
Randi Krogsgaard, IR & Corporate Communications
Tel # +45 2320 1001

About Affitech
Affitech AS is a publicly traded (NASDAQ OMX Copenhagen exchange) human
therapeutic antibody company headquartered in Copenhagen, Denmark with R&D
facilities in Oslo, Norway. The company utilizes a range of proprietary antibody
technologies for the discovery of fully human antibodies for application in
oncology, inflammation and other disease areas. CBAS™ (Cell Based Antibody
Selection) is Affitech's premier discovery engine for the isolation of lead
antibodies to cell surface molecules in situ. Several of the Company's
proprietary product candidates were generated by CBAS™. Further information is
available at www.affitech.com.

Disclaimer
This news release contains forward-looking statements and forecasts
based on uncertainty, since they relate to events and depend on circumstances
that will occur in the future and which, by their nature, will have an impact on
results of the financial condition and operations of Affitech A/S. There are
many factors that could cause actual results and developments to differ
materially from those expressed or implied by these forward-looking statements
and forecasts. These factors include, among other things, risks associated with
technological development, the risk that research & development will not yield
new products that achieve commercial success, the impact of competition, the
ability to transact viable and profitable commercial deals, the risk of
non-approval of patents not yet granted, and difficulties of obtaining relevant
governmental approvals for new products.
No expressed or implied representations or warranties are given concerning
Affitech A/S or the accuracy or completeness of the information provided herein,
and no claims shall be made by the recipient of this news release by virtue of
the information contained herein. 
 
This is an English translation of the Group's first six months announcement for
2010 made in Danish. In case of any discrepancies between the Danish version and
this English translation thereof, the Danish version shall prevail.

2q_2010_report_uk_final.pdf